UPC CFI 40/2025
Jan 22, 2025·EP3167888 Unitary patent · TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT
- Case details
- StatusCase ClosedActionGenericCategoryCosts assessments
- Parties
- Claimants
- Samsung Bioepis NL B.V.Operating co.
Representatives- Peter Meyer-Simmons & Simmons
- Andrea Ritter-Simmons & Simmons
- Division
- Hamburg LD
- Technology
- ChemistryBiotechnology · Pharmaceuticals
- Language
- —
- EPO Opposition
- Samsung Bioepis NL B.V.Withdrawn2024-05-02
- Amgen Technology (Ireland) Unlimited CompanyWithdrawn2024-10-28
- Salute HC Ilaç Pazarlama A.S.Admissible2025-01-31
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Hamburg LD | Locked |
| Judge Sabine Klepsch | Locked |
| Judge Alima Zana | Locked |
| Judge Stefan Schilling | Locked |
| Judge Rudi Goedeweeck | Locked |
At the UPC: Samsung Group (57 cases)·AstraZeneca Group (13 cases)
This dispute contains 6 other proceedings
UPC CoA 744/2025·UPC CFI 674/2025·UPC CFI 51/2025·UPC APP 43786/2024·UPC CoA 402/2024 and 1 more
3 other defendants litigating the same or a related patent
Start a free trial to see how each one ended.
More cases: Hamburg LD·2025
- 2025-08-01Application For CostsPublic
Summary: Decision of Hamburg Local Division in Samsung Bioepis NL B.V. v Alexion Pharmaceuticals (EP 3 167 888) assessing the costs of appeal proceedings following the Court of Appeal's rejection (20 December 2024) of Alexion's appeal against the dismissal of its application for provisional measures against Samsung Bioepis' Epysqli biosimilar. The court allowed the costs for UPC representatives and patent attorneys but reduced costs claimed for UK solicitors whose involvement (at higher cost than the actual UPC representatives) was not demonstrated to be necessary.
Show the legal issues (3)
- Costs assessment for appeal proceedings under R. 150-152 RoP
- Necessity and proportionality of UK solicitors' costs in UPC proceedings
- Ceiling for recoverable costs
| Document title | Date | Public |
|---|---|---|
| Application-For-Costs-Decision-Outcome | 2025-08-05 | Not public |
| Headnote-and-Keywords | 2025-08-01 | Not public |
| Order with grounds | 2025-08-01 | Not public |
| Order with grounds | 2025-08-01 | Public |
| Order with grounds | 2025-08-01 | Public |
| Order with grounds | 2025-08-01 | Not public |
| Receipt | 2025-07-23 | Not public |
| 20250404_Alexion_vs_SB12_EP888_UPC_CFI_40_2025_Further_comment_defendant_Redacted | 2025-07-23 | Not public |
| 20250120_SB12_UPC_Alexion_vs_SB_EP888-request_for_cost_recovery_Redacted | 2025-07-23 | Not public |
| Exhibit_S_S_01 | 2025-07-23 | Not public |
| Exhibit_S_S_03 | 2025-07-23 | Not public |
| Exhibit_S_S_04 | 2025-07-23 | Not public |
| Exhibit_S_S_02 | 2025-07-23 | Not public |
| 20250723_Alexion_vs_SB12_Request_for_Confidentiality_R_262.2_UPC_CFI_40_2025 | 2025-07-23 | Not public |
| Comments | 2025-07-14 | Not public |
| Exhibit FBD-C 1 | 2025-07-14 | Not public |
| Anhoerung | 2025-07-02 | Not public |
| Exhibit_S_S_03 | 2025-04-04 | Not public |
| Exhibit_S_S_06 | 2025-04-04 | Not public |
| 20250404_Alexion_vs_SB12_EP888_UPC_CFI_40_2025_Further_comment_defendant_re_cost_decision | 2025-04-04 | Not public |
| Exhibit_S_S_05 | 2025-04-04 | Not public |
| Exhibit_S_S_02 | 2025-04-04 | Not public |
| Exhibit_S_S_01 | 2025-04-04 | Not public |
| Exhibit_S_S_04 | 2025-04-04 | Not public |
| Anhoerung | 2025-03-18 | Not public |
| Comments | 2025-03-17 | Not public |
| Anhoerung | 2025-03-07 | Not public |
| Panel-Appointment | 2025-02-04 | Not public |
| Receipt | 2025-01-24 | Not public |
| 20250124_SB12_UPC_Alexion_vs_SB_EP888_Request_for_referral_of_Application_for_costs_to_Court_of_First | 2025-01-24 | Not public |
| Receipt | 2025-01-22 | Not public |
| Acknowledgement-of-lodging | 2025-01-20 | Not public |
| Application for cost recovery | 2025-01-20 | Not public |